Four novel triterpenoid alkaloids, siragrosvenins A-D (), and two new cucurbitane-type triterpenoids, siragrosvenins E-F (, ), together with eight known analogs (), were isolated from the roots of . Compounds possessed a rare cucurbitane-type triterpenoid scaffold, featuring an extra pyrazine unit the Strecker reaction in the cucurbitane framework. Compound displayed a 6/6/6/5/6/5-fused polycyclic ring system, with an uncommon fused furan and pyran ring in the side chain. All the structures were characterized by extensive spectroscopic analysis, including HRESIMS, NMR, and X-ray crystallographic data. It is worth noting that the DP4 analysis method was applied for the first time to determine the absolute configurations of the trihydroxybutyl moiety in the side chain of compounds . cytotoxicity screening found that compounds and exhibited remarkable cytotoxic activities against three cell lines with IC values ranging from 1.44 to 9.99 μM. Siragrosvenin D shows remarkable cytotoxic activity on MCF-7 cells. As a result, it inhibited the proliferation of MCF-7 cells and reduced their viability the induction of G2/M phase arrest and significantly induced apoptosis in MCF-7 cells.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099095 | PMC |
http://dx.doi.org/10.3389/fchem.2022.885487 | DOI Listing |
PLoS One
January 2025
Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
This study presents T-1-NBAB, a new compound derived from the natural xanthine alkaloid theobromine, aimed at inhibiting VEGFR-2, a crucial protein in angiogenesis. T-1-NBAB's potential to interacts with and inhibit the VEGFR-2 was indicated using in silico techniques like molecular docking, MD simulations, MM-GBSA, PLIP, essential dynamics, and bi-dimensional projection experiments. DFT experiments was utilized also to study the structural and electrostatic properties of T-1-NBAB.
View Article and Find Full Text PDFAssay Drug Dev Technol
January 2025
Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education & Research - Autonomous, Anantapur, Andhra Pradesh, India.
Front Oncol
January 2025
HEALTH BioMed Research & Development Center, Health BioMed Co., Ltd., Ningbo, Zhejiang, China.
Introduction: Breast cancer is one of the most common cancers in women and poses a serious threat to women's health. Circular RNAs (circRNAs) have been found to be specifically expressed in cancers and regulate the growth and death of tumor cells. The role of circRNAs in breast cancer remain unknown.
View Article and Find Full Text PDFJ Exp Pharmacol
January 2025
University Center of Excellence for Nutraceuticals, Bioscience and Biotechnology Research Center, Bandung Institute of Technology, Bandung, West Java, Indonesia.
Purpose: A promising feature of marine sponges is the potential anticancer efficacy of their secondary metabolites. The objective of this study was to explore the anticancer activities of compounds from the fungal symbiont of on breast cancer cells.
Methods: In the present research, , an endophytic fungal strain derived from the marine sponge was successfully isolated and characterized.
Front Mol Biosci
January 2025
Department of Biochemistry, Faculty of Agriculture, Zagazig University, Zagazig, Egypt.
Introduction: This study investigated the tryptic hydrolysis of β-lactoglobulin (BLG) for 30, 60, 90, and 120 min at 1/200 E/S (enzyme/substrate ratio, w/w) to prepare potentially anticarcinogenic peptides.
Methods: The properties of hydrolysates were characterized, including degree of hydrolysis, free amino acids, SDS-PAGE, FTIR, and antioxidant activity employing DPPH-assay, β-carotene/linoleic acid, and FRAP assay.
Results: BLG tryptic hydrolysate produced after 60 min hydrolysis recorded the highest antioxidant activity, and LCMS analysis revealed 162 peptides of molecular masses ranging from 800 to 5671Da, most of them are of hydrophobic nature.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!